Donate For Public and Patients Store Search

S045 - Melanoma and Mimics: New Diagnostic and Treatment Modalities

Sunday, March 3; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize the morphology and molecular pathology of different melanoma sub-types and borderline lesions.
  • Determine the appropriate patient management algorithm based on the combination of clinico-pathological correlation and, if necessary, molecular findings, as well as patient prognosis based on the new AJCC 8.
  • Discuss the newly available molecular tests and the new treatment options for melanoma such as targeted therapy, immunotherapy, and combination therapies.


This session will consist of a combination of formal lectures and interactive presentations. Different melanoma types and borderline melanocytic lesions will be discussed with emphasis on a combined approach spanning from clinico-pathological presentation to new molecular techniques available for diagnosis. The eighth edition of the AJCC criteria for melanoma prognosis will be explored. New treatment options and their adverse events will be discussed including target therapy and immunotherapy. The session will be directed to general Dermatologists, Dermato-oncologists, and Dermatopathologists.


  • Helmink, Beth: no financial relationships exist with commercial interests.
  • LeBoeuf, Nicole, MD: Bayer – Speaker/Faculty Education(H);
  • Mihm, Martin Charles Jr., MD: Alnylam – C(IP); BioCoz – A(NC); Caliber Imaging and Diagnostics Inc. – A(NC); MelaSciences – A(NC); Novartis – C(IP); Wiley & Sons, Inc. – C(IP);
  • Piris, Adriano, MD: no financial relationships exist with commercial interests.
  • Sullivan, Ryan, MD: Amgen – A(Fees); Array BioPharma – C(Fees); Biodesix, Inc. – A(Fees); Boehringer Ingelheim – O(Fees); Genentech, Inc. – C(Fees); Merck & Co., Inc – A(Fees); Novartis – A(Fees); Replimmune – A(Fees); Syndax Pharmaceuticals – A(Fees); WorldCare Clinical LLC – C(Fees);
  • Zakka, Labib, MD: no financial relationships exist with commercial interests.
Sunday, March 3
1:00 PM
Dr. Mihm / Atypical Melanocytic Proliferations: Diagnosis, Treatment, and New Molecular Findings
1:45 PM
Dr. Piris / Primary Cutaneous Melanoma: Morphology and Molecular Classification
2:15 PM
Dr. Zakka / The AJCC Staging System for Cutaneous Melanoma, 8th Edition
2:35 PM
Dr. Sullivan / The Role of BRAF Targeted Therapy in the Immunotherapy Era
3:05 PM
Dr. Helmink / Impact of the Microbiome on Immunotherapy
3:35 PM
Dr. LeBoeuf / Cutaneous Side Effects in Target Therapy and Immunotherapy
3:55 PM
All faculty / Panel Discussion and Questions
Event Details
  • Date
    Sunday, March 3
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 150B
  • CME Credits
  • Type
  • Martin Charles Mihm Jr., MD, FAAD
  • Adriano Piris, MD
  • Beth Helmink
  • Labib Zakka, MD
  • Nicole LeBoeuf, MD, FAAD
  • Ryan Sullivan, MD